Acromegaly is a rare and insidious condition that arises when the pituitary gland produces an excessive amount of growth hormone, usually due to a benign tumour. Because the physical changes associated with this disorder occur so slowly, the diagnostic process is often delayed by several years. In the United Kingdom, clinicians follow a precise biochemical and radiological pathway to confirm the overproduction of growth hormone and locate the underlying pituitary mass. This process involves a combination of highly sensitive blood tests, dynamic suppression studies, and advanced neuroimaging. Understanding how these tools work together is essential for patients to navigate their diagnosis and begin the necessary treatment to protect their long term metabolic and cardiovascular health.
What We’ll Discuss in This Article
- The role of IGF-1 as the primary biochemical screening tool.
- Why the Oral Glucose Tolerance Test is the “gold standard” for confirmation.
- The limitations of random growth hormone measurements.
- How MRI scans are used to locate and classify pituitary adenomas.
- The importance of assessing the entire pituitary hormone profile.
- Identifying “mass effect” through specialized visual field testing.
- Answers to common questions regarding the diagnostic timeline.
The Role of Insulin-like Growth Factor 1 (IGF 1) as a Screening Tool
The first step in investigating suspected acromegaly is almost always a blood test for Insulin like Growth Factor 1 (IGF 1). While the pituitary gland secretes growth hormone, most of its physical effects are carried out by IGF 1, which is produced in the liver in response to growth hormone stimulation. Unlike growth hormone, which is secreted in sharp pulses throughout the day and night, IGF 1 remains very stable in the bloodstream. This stability makes it an excellent “screening” marker that provides a reliable integrated measure of the average growth hormone activity over the previous twenty four hours.
In a clinical setting, a raised IGF 1 level is a strong indicator of acromegaly. However, it is vital that the results are compared against reference ranges that are specific to the patient’s age and gender. Growth hormone and IGF 1 levels naturally decline as we get older, so a level that is “normal” for a teenager would be significantly elevated for a fifty year old. According to clinical data from BMJ Best Practice, a serum IGF 1 concentration that is more than 1.3 times the upper limit of normal for a person’s age is highly suggestive of the condition. While a normal IGF 1 level usually rules out acromegaly, clinicians must be aware that pregnancy can cause a physiological rise in these levels, whereas liver disease or poorly controlled diabetes can sometimes lead to falsely low readings.
The Oral Glucose Tolerance Test (OGTT): The Gold Standard
If a patient has typical physical symptoms and a raised IGF 1 level, the next diagnostic step is the Oral Glucose Tolerance Test (OGTT). This is considered the “gold standard” confirmatory test for acromegaly. The test is based on a fundamental biological principle: in a healthy person, a high dose of sugar (glucose) should tell the brain to stop producing growth hormone. When you drink a concentrated glucose solution, the body’s blood sugar rises, which normally suppresses growth hormone to very low, almost undetectable levels.
In a person with acromegaly, the pituitary tumour acts autonomously. This means the tumour cells ignore the signal from the glucose and continue to pump out growth hormone regardless of the blood sugar level. In the UK, the protocol involves a patient fasting overnight and then drinking a 75 gram glucose solution. Blood samples are taken every thirty minutes over a two hour period to monitor how the growth hormone responds.
| Diagnostic Outcome | Growth Hormone (GH) Nadir | Clinical Interpretation |
| Normal Response | GH suppresses to < 0.4 mcg/L | Acromegaly is excluded |
| Equivocal Result | GH stays between 0.4 and 1.0 mcg/L | Requires further clinical review |
| Abnormal Response | GH remains > 1.0 mcg/L | Confirms GH overproduction |
Statistics published by The Society for Endocrinology confirm that this failure of suppression is the most definitive biochemical marker for the disease. It allows doctors to separate patients with true acromegaly from those who may have high growth hormone for other reasons, such as severe stress or malnutrition.
Why Random Growth Hormone Tests Are Unreliable
A common misconception is that a single, random blood test for growth hormone can diagnose acromegaly. In reality, a random test is often very misleading. Growth hormone is secreted in “spurts” or pulses throughout the day. A healthy person might have a very high growth hormone level for a few minutes after exercising or during deep sleep, which could be mistaken for acromegaly. Conversely, a person with acromegaly might happen to have their blood drawn during a natural “dip” in their tumour’s secretion, leading to a falsely normal result.
Because of this extreme variability, UK clinical guidelines strongly recommend against using random growth hormone levels as a standalone diagnostic tool. Instead, the focus remains on the stable IGF 1 marker and the dynamic suppression of the OGTT. According to research from NHS England, using random samples can lead to significant diagnostic errors, either causing unnecessary anxiety for healthy patients or missing cases of early disease.
Pituitary Imaging: Using MRI to Locate the Tumour
Once the biochemical tests have confirmed that the body is producing too much growth hormone, the final step is to find the source of the problem. In more than 95 percent of cases, this is a benign tumour located on the pituitary gland. The imaging tool of choice in the United Kingdom is a dedicated Magnetic Resonance Imaging (MRI) scan of the brain and pituitary.
A pituitary MRI is a highly specialized scan that uses powerful magnets to create thin, detailed slices of the gland. During the procedure, a contrast agent called gadolinium is often injected into a vein. This dye helps the radiologist distinguish between the healthy gland tissue and the tumour, which often takes up the dye differently. The MRI allows the medical team to see the exact size of the tumour and, crucially, its relationship to the surrounding structures. They can see if the tumour is pressing against the optic nerves (which control vision) or if it is invading the cavernous sinuses (large blood vessels on either side of the gland). This information is vital for planning surgery and predicting how successful the operation might be.
Differentiating Between Microadenomas and Macroadenomas
The results of the MRI scan allow clinicians to classify the tumour into two main categories based on size. This classification significantly impacts the patient’s long term management plan and their risk of secondary symptoms.
- Microadenomas: These are tumours less than 10 millimetres in diameter. They are often contained entirely within the gland and are less likely to cause pressure symptoms.
- Macroadenomas: These are tumours 10 millimetres or larger. Because they are larger, they are more likely to have been growing for several years.
According to data from the UK Acromegaly Register, the majority of patients with acromegaly are diagnosed with macroadenomas. This is because the symptoms of growth hormone excess are so subtle that the tumour has ample time to expand before it is identified. A macroadenoma can also cause “mass effect” symptoms such as persistent headaches or the loss of peripheral vision. If the MRI shows a large tumour that is close to the visual pathways, the patient will be referred for a formal visual field test to assess their sight.
Additional Diagnostic Assessments and Specialist Referrals
The diagnostic journey for acromegaly often extends beyond blood tests and scans. Because the pituitary is the “master gland,” a large tumour can sometimes crush the healthy parts of the gland, leading to a deficiency in other essential hormones. As part of the diagnostic workup, UK specialists will perform a full “pituitary profile.” This involves checking the levels of thyroid hormones, cortisol, and sex hormones (testosterone or oestrogen) to ensure that the rest of the endocrine system is still functioning correctly.
Furthermore, because chronic growth hormone excess can lead to complications elsewhere in the body, a new diagnosis often triggers a series of screening tests. These may include an echocardiogram to check the thickness of the heart muscle and a sleep study to investigate potential sleep apnoea. Statistics from the NHS highlight that around 40 percent of acromegaly patients may have some form of heart muscle thickening at diagnosis, making these baseline assessments a vital part of the specialized clinical pathway.
Final Conclusion
Diagnosing acromegaly requires a meticulous three stage approach: screening with a stable IGF 1 blood test, confirming growth hormone overproduction with an Oral Glucose Tolerance Test, and locating the tumour with a high resolution pituitary MRI. While the process can take several weeks, this structured pathway ensures that the diagnosis is accurate and that the extent of the tumour’s impact is fully understood. In the UK, this multidisciplinary approach allows for the development of a personalized treatment plan that addresses both the tumour itself and its systemic metabolic effects. Early and accurate diagnosis is the most effective way to restore hormonal balance and protect long term health. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
